<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922804</url>
  </required_header>
  <id_info>
    <org_study_id>K2vita</org_study_id>
    <nct_id>NCT01922804</nct_id>
  </id_info>
  <brief_title>Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification</brief_title>
  <acronym>K2vita</acronym>
  <official_title>Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Axellus</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the present study are to investigate the effect of vitamin K2 on bone turnover,
      bone mass, bone structure, glucose metabolism, and arteriosclerosis.

      Osteoporosis, diabetes, metabolic syndrome and cardiovascular disease are common diseases
      that affect large groups of people in the Western world.

      Our hypotheses is that vitamin K2 (MK-7) reduces undercarboxylated osteocalcin in
      postmenopausal women and reduces bone turnover and increases bone mineral density; increases
      insulin sensitivity and decreases indices of arterial calcification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis, diabetes, metabolic syndrome and cardiovascular disease are common diseases
      that affect large groups of people in the Western world.

      Our hypotheses is that vitamin K2 (MK-7) reduces undercarboxylated osteocalcin in
      postmenopausal women and reduces bone turnover and increases bone mineral density; increases
      insulin sensitivity and decreases indices of arterial calcification.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>p-undercarboxylated osteocalcin</measure>
    <time_frame>Change in undercarboxylated osteocalcin in plasma after 3 month treatment compared to baseline. Analysed in batch after the end of trial.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density</measure>
    <time_frame>Assessed after 3, 6, 12, 24 and 36 months</time_frame>
    <description>Change in bone mineral density measured by DXA scans (Dual energy x-ray absorptiometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial stiffness, pulse wave velocity</measure>
    <time_frame>Measured at baseline and after 6 months</time_frame>
    <description>Change in pulse wave velocity after 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>Measured at baseline and after 1 and 12 months.</time_frame>
    <description>Change in insulin sensitivity. Determined by HOMA-test (homeostasis model assessment), using fasting plasma glucose and insulin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone turnover markers</measure>
    <time_frame>Measured at baseline, after 1, 3, 6, 12, 24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone structure</measure>
    <time_frame>baseline and month 12</time_frame>
    <description>HRpQCT scans</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Metabolic Bone Disorder</condition>
  <arm_group>
    <arm_group_label>K2 vitamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K2 vitamin 375 microgram a day for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 tablet a day for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>K2 vitamin</intervention_name>
    <description>K2 vitamin tablet</description>
    <arm_group_label>K2 vitamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postmenopausal women

          -  60-80 years

          -  osteopenia

        Exclusion Criteria:

          -  Calcium metabolic, thyroid, liver or kidney disease

          -  Diabetes

          -  Obesity

          -  Myocardial infarction or other arteriosclerotic events

          -  Angina pectoris

          -  Vitamin D &lt; 50 nmol/L

          -  Treatment with vitamin K antagonists

          -  Use of vitamin K supplements in the last month or for more than 3 months at any time

          -  Treatment with drugs with known effects on bone metabolism or glucose metabolism.

          -  Smoking in the last 12 months

          -  Drug or alcohol abuse

          -  Allergy to calcium, vitamin D or vitamin K.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sofie RÃ¸nn, cand.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Medicine THG</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

